Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

9.7%

7 terminated/withdrawn out of 72 trials

Success Rate

88.1%

+1.6% vs industry average

Late-Stage Pipeline

28%

20 trials in Phase 3/4

Results Transparency

17%

9 of 52 completed trials have results

Key Signals

3 recruiting9 with results6 terminated

Enrollment Performance

Analytics

Phase 2
29(43.9%)
Phase 1
17(25.8%)
Phase 3
15(22.7%)
Phase 4
5(7.6%)
66Total
Phase 2(29)
Phase 1(17)
Phase 3(15)
Phase 4(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (72)

Showing 20 of 72 trials
NCT06997159Phase 2Not Yet Recruiting

A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).

Role: lead

NCT05593666Phase 2Completed

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

Role: lead

NCT05433350Phase 2Recruiting

Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients

Role: lead

NCT05957978Phase 2Completed

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Role: lead

NCT03087955Phase 2Completed

Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense

Role: lead

NCT04515186Phase 3Completed

Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World

Role: lead

NCT05449717Completed

Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan

Role: collaborator

NCT05256017Phase 2Completed

Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects

Role: lead

NCT03974178Phase 2Completed

Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense

Role: lead

NCT03025789Phase 3Completed

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

Role: lead

NCT04913610Phase 2Terminated

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection

Role: collaborator

NCT06512714Recruiting

Mycetoma Retrospective Data Collection

Role: lead

NCT06514183Terminated

Eumycetoma Long-term Post-Treatment Follow-Up Study

Role: lead

NCT03086226Phase 2Completed

Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan

Role: lead

NCT03981523Phase 2Completed

New Therapies and Biomarkers for Chagas Infection

Role: collaborator

NCT02589782Phase 2Completed

Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

Role: collaborator

NCT06356974Phase 3Not Yet Recruiting

Stop Transmission of Gambiense Human African Trypanosomiasis (STROgHAT)

Role: lead

NCT05180461Phase 2Active Not Recruiting

Emodepside Phase II Trial for Treatment of Onchocerciasis

Role: lead

NCT03129646Phase 3Completed

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Role: lead

NCT05645822Withdrawn

Screen and Treat Implementation for HAT Control

Role: collaborator